Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents Christine.

Slides:

Advertisements

Similar presentations

Volume 146, Issue 1, Pages e1 (January 2014)

Advertisements

Systematic Review of the Quality of Patient Information on the Internet Regarding Inflammatory Bowel Disease Treatments Morgan Langille, André Bernard,

The Role of Psychosocial Care in Adapting to Health Care Reform

Abnormal Liver Tests and Fatty Liver on Ultrasound

Thrombocytopenia With Abnormal Liver Function Tests

Ashwin N. Ananthakrishnan, Millie D. Long, Christopher F

Saurabh Dawra, Vishal Sharma, Usha Dutta

Issue Highlights Clinical Gastroenterology and Hepatology

Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies Welmoed K. Van Deen, Andrea E.

Nitsan Maharshak, Scott E. Plevy

Gauree Gupta, Ebbing Lautenbach, James D. Lewis

Celiac Disease and Persistent Symptoms

Fernando Velayos, Uma Mahadevan

Right Upper Quadrant Pain and a Normal Abdominal Ultrasound

Prevalence of Irritable Bowel Syndrome–type Symptoms in Patients With Celiac Disease: A Meta-analysis Anita Sainsbury, David S. Sanders, Alexander C.

Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis

Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review Marin J. de Jong,

A 31-Year-Old Patient With Colitis and Perianal Disease

Stephen A. Harrison, MD, FACP Clinical Gastroenterology and Hepatology

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease Matthias Jürgens, Jestinah M. Mahachie.

A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease Garret Cullen, Denise Keegan, Hugh.

Long-term Recurrence-free Survival After Standard Endoscopic Resection Versus Surgical Resection of Submucosal Invasive Colorectal Cancer: A Population-based.

Wireless Capsule Endoscopy Fragmentation in a Patient With Crohn's Disease Marcia Henriques de Magalhães Costa, Andre da Luz Moreira, Cyrla Zaltman Clinical.

Patients With Barrett’s Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer Christine Kestens, G.

Todd H. Baron, Patrick S. Kamath, Robert D. McBane

Andree Koop, Michael J. Bartel, Dawn Francis

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled.

Miguel Regueiro, Kevin E. Kip, Leonard Baidoo, Jason M

Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model Corey A. Siegel, Samuel R.G. Finlayson,

Systematic Review of the Quality of Patient Information on the Internet Regarding Inflammatory Bowel Disease Treatments Morgan Langille, André Bernard,

Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased Fiona D.M. van Schaik, Martijn G.H.

Endoscopic Therapy for Barrett's Esophagus

Alison de Lima, Zuzana Zelinkova, Annemarie G. M. G. J. Mulders, C

Traveling Internationally: Avoiding and Treating Travelers' Diarrhea

AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review Jean-Frederic Colombel,

Leon P. McLean, Jonathan S. Chun, Raymond K. Cross

Mild Enteropathy Celiac Disease: A Wolf in Sheep's Clothing?

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab Fernando.

Serotonin Synthesis and Uptake in Symptomatic Patients With Crohn’s Disease in Remission Itta M. Minderhoud, Bas Oldenburg, Marguerite E.I. Schipper,

Abnormal Liver Tests and Fatty Liver on Ultrasound

Gastroenterology in a New Era of Accountability: Part 2

New Models of Gastroenterology Practice

Dushyant Singh, Reetu Singh, Wendell K. Clarkston

David H. Bruining, William J. Sandborn

Najat Mourra, Nikias Colignon Clinical Gastroenterology and Hepatology

Peter Bytzer Clinical Gastroenterology and Hepatology

Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging Konstantinos Karmiris, Didier.

High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease Shailja C. Shah,

Patient-Reported Outcomes of Cirrhosis

Colorectal Cancer Screening: How to Stop a Moving Target

Effects of Different Coping Strategies on Physical and Mental Health of Patients With Irritable Bowel Syndrome Lilian Dindo, PhD Clinical Gastroenterology.

Issue Highlights Clinical Gastroenterology and Hepatology

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis

Thrombocytopenia With Abnormal Liver Function Tests

Palmoplantar Pustulosis and Acrodermatitis in a Patient Treated With Infliximab for Crohn's Sacroiliitis Jürg Wermuth, Fabiola Kind, Michael Steuerwald

Sustained Clinical Benefit and Tolerability of Methotrexate Monotherapy After Thiopurine Therapy in Patients With Crohn's Disease Margien L. Seinen,

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Christopher Hung, Desmond Leddin

Coagulation in Liver Disease: A Guide for the Clinician

Issue Highlights Clinical Gastroenterology and Hepatology

Risk of Pancreatitis in Patients With Celiac Disease: Is Autoimmune Pancreatitis a Biologically Plausible Mechanism? John S. Leeds, David S. Sanders

Volume 146, Issue 1, Pages e1 (January 2014)

Coloduodenal Fistula in Crohn’s Disease

Adverse Outcomes: Why Bad Things Happen to Good People

Medical Therapy for Refractory Pediatric Crohn’s Disease

The Role of Psychosocial Care in Adapting to Health Care Reform

Jordan E. Axelrad, Simon Lichtiger, Amrita Sethi

Karanprit Singh, Prateek Chapalamadugu, Peter Malet

Choosing Wisely and the Perceived Drivers of Endoscopy Use

Presentation transcript:

Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents Christine Kestens, Martijn G.H. van Oijen, Charlotte L.J. Mulder, Ad A. van Bodegraven, Gerard Dijkstra, Dirk de Jong, Cyriel Ponsioen, Bas A.C. van Tuyl, Peter D. Siersema, Herma H. Fidder, Bas Oldenburg Clinical Gastroenterology and Hepatology Volume 11, Issue 7, Pages 826-831 (July 2013) DOI: 10.1016/j.cgh.2013.01.012 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Rates of response for patients with CD treated with anti-TNFα. (A) Percentage of patients with a response treated with anti-TNFα and (B) a comparison with and without concomitant use of immunomodulators. *Response rates of IFX with and without immunomodulators were both significantly different in favor of combined treatment after 1 and 2 years. Clinical Gastroenterology and Hepatology 2013 11, 826-831DOI: (10.1016/j.cgh.2013.01.012) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Remission in patients with CD divided by (A) type of anti-TNFα given and (B) with and without concomitant use of immunomodulators. Clinical Gastroenterology and Hepatology 2013 11, 826-831DOI: (10.1016/j.cgh.2013.01.012) Copyright © 2013 AGA Institute Terms and Conditions